Posts tagged Psychiatry Products
Stifel downgrades Alcobra to hold

Stifel downgraded Alcobra (NASDAQ:ADHD) to “hold” from “buy” and slashed its price target to $3 from $17 after the FDA issued a clinical hold on the company’s Phase 3 study of metadoxine extended release (MDX) in adult patients with ADHD, known as the “MEASURE” study.

Shares of Alcobra were quoted at $2.55 at midday Friday.

Read More